First time I've seen the diagnostic company website's new update. Pretty informative and they've come a long way. They've brought in at least 10 million dollars in private investment lately as well. Yes there are 3 different tests used. All 3 show different "windows" into synaptic health. The one presented at AAIC is almost full proof accurate based on the autopsy results and a different look into the synaptic window from PKCe levels. The PKCe assay is Sensitivity: 100%, Specificity 96% per autopsy research and the 3rd test similar as well. What the PKCe essay can be used for as well is distinguishing the stage of AD, the pace of decline, etc. I can probably go back and find the specific research for the patents if I have the time.
Some asked if this is confirmative of our MOA? I mean it is our MOA and we know PKCe levels (and dozens of other biometric metric levels) can be lower in AD patients. Can you imagine a test that can diagnose and measure AD levels based on a measurement (PKCe) so impacted by bryostatin? It's either big, or it's not. I guess we'll have to wait a few months to know for sure.